Trusted Biotechnology Investments Experts

AI meets biotech — straight from Zug, Switzerland Get the latest AI news, learn must-know AI tools, and keep up with Biotech news in just 5 minutes a week. Join our readers growing their careers with the AIxBiotech newsletter. Founded by executives who have led global biotech and tech teams, AIxBiotech is on a mission to make AI practical for themodern biotech office. In just a few months, we’ve attracted a fast-growing audience of biotech professionals and innovation leaders — from early-stage founders to Fortune 500 executives. Our readers span Europe and North America, with a strong base in the U.S. and Switzerland. We’re building organically, one engaged reader at a time — with the ambition to reach 500K professionals within our first year.

Authentic technology recruitment leader with expertise in executive talent acquisition and building high performance recruitment teams, primarily within the tech/digital/creative disciplines.

Vardan Ter-Antonyan is a pharmaceutical research and development executive with more than 20 years of experience advancing products from concept through commercialization. His expertise spans drug formulation, pharmaceutical development, manufacturing scale-up, quality systems, regulatory strategy, and commercialization across pharmaceuticals, medical devices, nutraceuticals, cannabinoids, and medical technologies. Throughout his career, Vardan has led multidisciplinary R&D teams, developed novel drug delivery systems, optimized manufacturing processes, and helped organizations bring innovative products to market while navigating complex regulatory requirements. His technical expertise includes lipid-based drug delivery systems, nanoemulsions, self-emulsifying drug delivery systems (SEDDS/SNEDDS), liposomes, controlled-release technologies, and formulation development for poorly water-soluble compounds. In addition to his scientific leadership, Vardan is passionate about bridging the gap between research and commercial success. He regularly advises companies on product development strategy, technology commercialization, operational excellence, and innovation management. His work combines deep scientific knowledge with practical business insight, enabling organizations to accelerate development timelines, improve product quality, and reduce technical risk. Vardan is also an author, speaker, and industry thought leader who enjoys sharing evidence-based perspectives on pharmaceutical innovation, drug delivery, biotechnology, diagnostics, manufacturing, and executive leadership. He welcomes opportunities to provide expert commentary for journalists covering advances in pharmaceutical science, healthcare innovation, biotechnology, regulatory affairs, and emerging medical technologies.

Vincent Caradec is the French CEO and Co-Founder of Healthi Life (healthi-life.com), Bangkok's Urban Longevity House — a physician-led longevity, preventive and regenerative medicine clinic serving 50+ nationalities. Available for expert commentary on: - Building a longevity clinic in Asia - Medical tourism market trends in Thailand and Southeast Asia - CEO insights on preventive medicine adoption - GLP-1 weight management market (Tirzepatide, Retatrutide, Mounjaro, Wegovy) - Stem cell, exosome and NAD+ regenerative therapies - 300+ biomarker testing programs and longevity diagnostics - Wellness industry business strategy and pricing - Asian healthcare entrepreneurship Healthi Life operates an integrated longevity center offering check-ups, 3-12 month longevity programs, corporate wellness contracts and advanced regenerative therapies (stem cells, exosomes, NAD+, peptides, IV therapy). French national based in Bangkok. Fluent in English and French. Available for interviews on Zoom, Google Meet, WhatsApp.

Founder of IngredientMD, a supplement intelligence platform powdered by most clinical data available. What's important, we communicate in language humans will understand instead. It all starts from individual ingredients instead of product name, claims, and anything else. Product is what's inside instead of what perception is being made. In our analysis of 500+ supplement products, we found 42% had at least one key ingredient below clinically studied doses. I focus on bringing evidence-based analysis to consumer supplement decisions.

Jason White is the CEO and majority owner of LEC Partners, a Cambridge, MA-based advisory firm that has helped clients navigate the bioeconomy for over 30 years. He works with investors, developers, and operators to evaluate technologies, structure projects, and reduce technical and commercial risk in areas such as renewable fuels, biomaterials, and low-carbon feedstocks. Jason’s background spans four continents and multiple industries, including fintech, medtech, and renewable energy. Before leading LEC Partners, he ran a fintech and consulting firm in Shenzhen, advised the founder of a medical device startup in Switzerland, and managed C-suite relationships with major retailers, banks, IT firms, and private equity investors. This mix of operating, deal-making, and cross-border experience gives Jason a practical perspective on how emerging technologies move from concept to bankable projects. Journalists often turn to him for clear explanations of complex topics such as project development risk, bioeconomy policy impacts, and how investors are underwriting new technologies in real deals. Jason is based in the Greater Boston area with his family, where he is raising two sons, coaching youth sports, and staying closely engaged with the next generation of problem-solvers.

With a PhD in molecular genetics and as a specialist in data science, Céline Chantry-Darmon has over twenty years of experience in biomedical research and complex data analysis. As Scientific Director at Tekkare, she works on developing trustworthy artificial intelligence for healthcare. She is also committed to promoting inclusive and responsible artificial intelligence, and to advancing women in science and technology.

Dr. Sarassawadee Suwanjinda ("Dr. Petch") is Co-Founder and Chief Medical Strategy Officer at Healthi Life, Bangkok's Urban Longevity House. Certifications: - International Board of Lifestyle Medicine (IBLM) - International Society for Stem Cell Application (ISSCA) - Certified Board of Anti-Aging Medicine (CBAM) - American Academy of Aesthetic Medicine (AAAM) - Certificate in Aesthetic Medicine 10+ years of clinical experience in longevity, regenerative, functional, and lifestyle medicine. Available for expert medical commentary on: - Longevity medicine and healthspan extension - Stem cell and exosome therapy safety - NAD+ IV therapy and mitochondrial health - Peptide therapy and physician oversight (Tirzepatide, Retatrutide, BPC-157) - Hormone optimization (testosterone, perimenopause) - 300+ biomarker health check-ups - Functional medicine for chronic conditions Located in Ekkamai, Bangkok. Serving 50+ nationalities.

Dr. Robert Abraham is a regenerative medicine consultant and healthcare strategy advisor with more than a decade of experience operating multi-location healthcare practices. He earned his Bachelor of Science in Health Sciences and Biology from the University of Central Florida before pursuing advanced training in clinical operations and regenerative-focused program development. Based in Florida, Dr. Abraham has worked with healthcare organizations throughout the Orlando region and nationwide, advising clinics on structured implementation, operational systems design, revenue forecasting, and compliance-conscious growth within regenerative medicine and wound care services. In addition to his consulting work, he serves as Chief Executive Officer of Cross Biotech, a biologics distribution company supporting providers in aligning product access with disciplined operational frameworks. His work emphasizes infrastructure-driven expansion, leadership accountability, and sustainable healthcare systems.

Vignesh Coumarane is the founder of InvestEd (the-invested.com) and author of the Financial Decision Intelligence Framework — a simulation-native architecture that lets anyone model financial decisions before committing, without surrendering bank credentials or personal data. He serves as Manager of Data Analytics at Lincare (a Linde Company), with over a decade of experience across finance, healthcare, and AI-driven analytics. A 4x LinkedIn Top Voice and Times Square Top Data 100 honoree, he writes the Before You Invest newsletter on structured thinking for financial decisions in an AI world.

Achal Shah is VP of Strategic Development at Monetrey Mushrooms, a food and biotech company in the agriculture space, and a published contributor to AgFunderNews. With over 10 years of experience at the intersection of food, agriculture, and innovation, Achal has advised leading agribusinesses at McKinsey & Company and served as Global Strategy Lead and Chief of Staff to the CEO at RiceTec, a global seed company operating across the U.S., India, and Brazil. He has led strategies spanning seed genetics, sustainable farming, agri-biotech commercialization, digital transformation, and M&A — and spearheaded a multi-continent initiative to drive hybrid rice adoption that reduced methane emissions, cut water consumption, and improved profitability for smallholder farmers. Achal holds an MBA from the Kellogg School of Management and a Master’s in Design Innovation from Northwestern University. He is available to comment on agribusiness strategy, agricultural biotech, food system innovation, sustainable farming, and emerging trends shaping the global agriculture industry.

Dr. Akshaya Srikanth Bhagavathula is an Associate Professor of Epidemiology at North Dakota State University, internationally recognized for his pioneering work at the intersection of digital epidemiology, pharmacovigilance, and artificial intelligence. His research harnesses advanced statistical modeling and AI to track and predict health behaviors, medication safety, and disease patterns in real time—bridging traditional epidemiology with next-generation digital health analytics. Dr. Bhagavathula has published more than 250 peer-reviewed articles in leading journals, including Annals of Epidemiology, JAMA Network Open, and Lancet Digital Health. His work has been widely cited and featured in major media outlets such as The New York Times, where he discussed the real-world safety of GLP-1 receptor agonists like semaglutide (Ozempic, Wegovy, Mounjaro). Recognized among the Stanford–Elsevier Top 2% of Scientists (2019–2024) and elected as a Fellow of the American College of Epidemiology, Dr. Bhagavathula is known for translating complex data into actionable insights that shape public health policy and clinical practice. His ongoing projects include NIH- and NSF-aligned initiatives on AI-powered overdose forecasting, digital twins for public health, and real-world drug safety surveillance using explainable machine learning. With a decade of experience spanning more than two dozen countries and collaborations with organizations such as WHO, USAID, and UNICEF, Dr. Bhagavathula brings a global, data-driven, and human-centered approach to solving modern health crises.

I’m an entrepreneur working at the intersection of AI, product execution, and healthcare access. Over the last decade I’ve built and led teams that turn new technology into practical tools for real businesses. I co-founded BotsCrew in 2016, grew it into a global AI services company, and later joined the CourtAvenue collective, where we help large enterprises adopt generative AI with speed and precision. I also founded AllClinicalTrials.com and Curify, two platforms focused on making it easier for patients to find and enroll in legitimate clinical trials. That work started from a personal experience trying to find treatment options for a family member, and it pushed me toward building products that remove friction from complex systems. My background is in applied mathematics and AI, but most of my learning came from building things fast, talking to customers, and fixing what didn’t work. I’m especially interested in how generative AI will reshape operations, customer experience, and decision-making in large organizations. I try to share what I learn - both the wins and the mistakes - so others can move faster.

Surojit Chakraverti is the founder of Third Wave Capital, an independent investment management firm focused on long-short investing across global healthcare and technology. He has worked across public markets investing, investment banking, M&A advisory, valuation and corporate training. Previously, Surojit worked in Healthcare M&A at Rothschild & Co and Industrials M&A at Citi, advising on transactions across the healthcare, pharmaceutical, industrial and business services sectors. Today, he combines investing, advisory work and financial education, helping professionals and organisations think through markets, valuation, capital allocation, deal-making and decision-making under uncertainty. He also writes 2nd Order Thoughts, a markets and investing publication focused on second-order consequences, incentives, behavioural patterns and overlooked risks across public markets and corporate finance.

Vijay Amin is the Founder & CEO of VertiComply, an AI-powered no-code platform that generates owned, exportable, production-ready healthcare app code with 15+ compliance frameworks enforced at the code level — including HIPAA, GDPR, SOC 2, FDA 21 CFR Part 11, EU AI Act, ISO 27001, HITRUST, ABDM, and DPDP. With 21 years of enterprise IT experience across healthcare, cloud infrastructure, and AI, Vijay has spent his career at the intersection of highly regulated industries and emerging technology. He founded VertiComply after seeing the same pattern repeat across digital health teams: AI-generated code that looked compliant but failed the moment a real audit, security review, or partner onboarding arrived. The platform is built for healthcare startups, digital health teams, and non-technical founders who need to ship fast without compromising on ownership, security, or regulatory rigor. Vijay's areas of expertise include: 1. Healthcare data privacy and HIPAA compliance 2. AI-generated code risk in regulated industries 3. The EU AI Act and its impact on US healthcare and digital health companies 4. Multi-framework compliance overlap (HIPAA + GDPR + FDA 21 CFR Part 11 + SOC 2) 5. No-code and low-code platforms for healthcare app development 6. Cloud security and infrastructure for HIPAA-regulated workloads 7. Compliance challenges for early-stage healthcare and digital health startups 8. India's digital health stack (ABDM, DPDP Act) and cross-border compliance He is available for expert quotes, background commentary, and contributed articles on healthcare IT, AI compliance, cybersecurity, digital health, and the evolving regulatory landscape for AI in regulated industries. Vijay can also connect journalists with healthcare CTOs, compliance officers, and digital health founders within VertiComply's network for additional sourcing. Based in Ahmedabad, India, Vijay leads VertiComply alongside co-founder and CTO Garvita Solanki, who brings 15 years of engineering experience.

Andrea is an entrepreneur & global expert in 𝐬𝐮𝐬𝐭𝐚𝐢𝐧𝐚𝐛𝐢𝐥𝐢𝐭𝐲, 𝐠𝐫𝐞𝐞𝐧 𝐭𝐞𝐜𝐡 𝐚𝐧𝐝 𝐞𝐧𝐞𝐫𝐠𝐲 𝐭𝐫𝐚𝐧𝐬𝐢𝐭𝐢𝐨𝐧. He is the founder & "Chief Earth Officer" (i.e. a CEO on a mission for our planet) at 𝐢𝐥𝐥𝐮𝐦𝐢𝐧𝐞𝐦.𝐜𝐨𝐦, a leading sustainability information and data platform, and one of Angel List’s ‘𝐓𝐨𝐩 𝐃𝐢𝐠𝐢𝐭𝐚𝐥 𝐒𝐭𝐚𝐫𝐭𝐮𝐩 𝐢𝐧 𝐄𝐮𝐫𝐨𝐩𝐞’. In 2024, illuminem achieved "the most participated round by key climate investors worldwide" and "the region's highest valuation for an early-stage climate company". Andrea is also the 𝐲𝐨𝐮𝐧𝐠𝐞𝐬𝐭 𝐩𝐫𝐨𝐟. 𝐚𝐭 𝐇𝐄𝐂 𝐏𝐚𝐫𝐢𝐬 (Europe's #1 business school), where he teaches Europe’s only Greentech course, with the goal of developing the next generation of sustainability leaders. Previous to illuminem, he served as the 𝐁𝐨𝐬𝐭𝐨𝐧 𝐂𝐨𝐧𝐬𝐮𝐥𝐭𝐢𝐧𝐠 𝐆𝐫𝐨𝐮𝐩’𝐬 (𝐁𝐂𝐆) 𝐆𝐥𝐨𝐛𝐚𝐥 𝐆𝐫𝐞𝐞𝐧 𝐂𝐡𝐚𝐦𝐩𝐢𝐨𝐧, leading projects on sustainable investments and innovation for multinationals & governments. Andrea has been recognized by the 𝐔𝐧𝐢𝐭𝐞𝐝 𝐍𝐚𝐭𝐢𝐨𝐧𝐬 as one of the 50 𝐆𝐥𝐨𝐛𝐚𝐥 '𝐈𝐦𝐩𝐚𝐜𝐭 𝐌𝐚𝐤𝐞𝐫𝐬' ("civil society leaders making the change we need to see"), and by Startup Italia as one of '𝐈𝐭𝐚𝐥𝐲’𝐬 𝐋𝐞𝐚𝐝𝐢𝐧𝐠 𝐈𝐧𝐧𝐨𝐯𝐚𝐭𝐨𝐫𝐬'. He is the Sustainability & Innovation 𝐂𝐨𝐥𝐮𝐦𝐧𝐢𝐬𝐭 𝐟𝐨𝐫 𝐀𝐮𝐬𝐭𝐫𝐢𝐚’𝐬 𝐦𝐚𝐢𝐧 𝐧𝐞𝐰𝐬𝐩𝐚𝐩𝐞𝐫, Der Standard; a published author in the Journal of Financial Engineering; and a speaker at events hosted by COP, Davos, and universities around the world. His latest TEDx on ESG has become “the most-watched talk in Italian on sustainability.”

Tatiana Anderson is a tropical plant expert with over 20 years of hands-on experience growing and caring for tropical and subtropical plants. Her work focuses on fruit trees, flowering plants, and climate-sensitive species, with practical guidance based on real growing conditions. She works with a US-based tropical plant nursery that ships plants nationwide and contributes to a large online plant encyclopedia documenting thousands of plant species. Tatiana specializes in plant identification, variety selection, cold protection, and helping gardeners avoid common growing mistakes.

I build infrastructure for emerging technology transitions—and have been doing it for 20 years. Many know me for my work in digital health, where I spent two decades helping the industry understand how technology shapes behavior and decision-making. That work taught me something: every major platform shift creates new vulnerabilities and opportunities, and the companies that thrive are the ones who see them early. Today I'm focused on the agentic era—where AI systems operate autonomously and require fundamentally new approaches to security, commerce, and trust. WHAT I'VE SHIPPED Co-author of the #1 bestselling book ePatient 2015: 15 Surprising Trends Changing Healthcare (featured in Bloomberg, Forbes, and other publications). Co-founder of the FemAging Project, a global initiative driving women's health innovation. Creator of Femalytics, an AI-powered intelligence platform. Author of two FemAging Index studies, including one sponsored by AARP. Founder of Enspektos, LLC (est. 2005), which has evolved through Web 2.0, mobile, and ML eras—always at the intersection of emerging tech and real-world application. WHAT I'M BUILDING NOW AI Security Guard (aisecurityguard.io) is a multi-faceted platform for securing autonomous AI, combining protection APIs, product tooling, education, and original research on the agentic future.

I'm a Pharm.B student with a background in pharmacology and biochemistry, and the founder of NakedCompound.in — a research-backed supplement review platform built for Indian buyers. I specialize in analyzing clinical evidence behind supplement ingredients, evaluating label accuracy, identifying underdosed or adulterated products, and translating complex pharmacology into practical guidance for everyday consumers. My work covers protein supplements, creatine, ashwagandha, BCAAs, pre-workouts, and other sports nutrition compounds — with specific context around FSSAI regulations, Indian brand quality standards, and bioavailability in Indian dietary patterns. I'm available to comment on supplement science, sports nutrition, nutraceutical safety, ingredient interactions, and the Indian wellness market.

Ivan Patriki is a premier fintech entrepreneur, quantitative trading advocate, and digital marketing expert widely recognized as the co-founder of QuantMap and the CEO of Amora Media Group. Professionally known across digital platforms as Artizt, Patriki commands a cross-platform audience of over 350,000 followers where he actively reshapes the retail investment industry by challenging predatory marketing and providing institutional-grade data analytics. As a respected thought leader, media commentator, and industry educator, his insights frequently appear in top-tier financial publications including Investing.com, Benzinga, and FXStreet. He leverages deep expertise in audience development, digital media strategy, and financial commentary to dismantle the "finfluencer" epidemic, move retail traders away from gut feelings toward data-driven quantitative models, and teach creators the mechanics behind generating hundreds of millions of views while maintaining absolute transparency. - www.ivanpatriki.com